{"product_id":"critical-care-nursing-9780470958568","title":"Critical Care Nursing","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eProviding an easy-to-use reference, \u003ci\u003eCritical Care Nursing\u003c\/i\u003e outlines best practice for the assessment, monitoring and treatment of critically ill adult patients. Each chapter includes research and evidence-based strategies for treating commonly-seen conditions.\u003c\/p\u003e \u003cp\u003eInitial chapters introduce ICU set-up and operation, the rapid response team, vitals measurement and shock management strategies. Subsequent chapters, structured by organ system, focus on care relating to specific organ function and dysfunction, including the respiratory, cardiovascular, neurologic, renal and gastrointestinal systems. Key information on monitoring for overdoses, special considerations in traumatic injury and end-of-life concerns is also included.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCritical Care Nursing\u003c\/i\u003e is a comprehensive and informative resource for experienced staff nurses and advanced practice nurses working with critically ill patients on ICUs, PCUs, transitional care units and within emergency care departments.\u003c\/p\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eContributors, xv  \u003cp\u003eCritical Care Nursing: Monitoring and Treatment for Advanced Nursing Practice, xvii\u003cbr\u003e \u003ci\u003eKathy J. Booker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Philosophy and treatment in US critical care units, 1\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKathy J. Booker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eUS critical care units, 1\u003c\/p\u003e \u003cp\u003eOrganization of critical care delivery, 1\u003c\/p\u003e \u003cp\u003eMonitoring and surveillance in critical care, 2\u003c\/p\u003e \u003cp\u003eSurveillance, 2\u003c\/p\u003e \u003cp\u003eNursing certification and competency in critical care units, 3\u003c\/p\u003e \u003cp\u003eUS national critical care organizations, 4\u003c\/p\u003e \u003cp\u003eAmerican Association of Critical Care Nurses, 4\u003c\/p\u003e \u003cp\u003eSociety of Critical Care Medicine, 5\u003c\/p\u003e \u003cp\u003eAcute care advanced practice nursing, 5\u003c\/p\u003e \u003cp\u003eClinical nurse specialists, 6\u003c\/p\u003e \u003cp\u003eAcute care nurse practitioners, 6\u003c\/p\u003e \u003cp\u003eCritical care and ACNP outcomes research, 7\u003c\/p\u003e \u003cp\u003eEvolution of families in the critical care unit, 8\u003c\/p\u003e \u003cp\u003eProgression and development of rapid response teams, 9\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Vital measurements and shock syndromes in critically ill adults, 13\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKathy J. Booker and Laura Kierol Andrews\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eMonitoring basic vital signs, 13\u003c\/p\u003e \u003cp\u003eTemperature monitoring, 14\u003c\/p\u003e \u003cp\u003eHypothermia, 14\u003c\/p\u003e \u003cp\u003eComplications of cooling, 15\u003c\/p\u003e \u003cp\u003eHyperthermia, 17\u003c\/p\u003e \u003cp\u003eHeatstroke management, 17\u003c\/p\u003e \u003cp\u003eMalignant hyperthermia, 17\u003c\/p\u003e \u003cp\u003eHeart rate monitoring, 18\u003c\/p\u003e \u003cp\u003eBlood pressure monitoring, 19\u003c\/p\u003e \u003cp\u003eOscillometric blood pressure measurement, 20\u003c\/p\u003e \u003cp\u003eAneroid measurement, 20\u003c\/p\u003e \u003cp\u003eArterial pressure measurement, 20\u003c\/p\u003e \u003cp\u003eRespiratory monitoring, 21\u003c\/p\u003e \u003cp\u003eCapnography, 21\u003c\/p\u003e \u003cp\u003eShock conditions in critically ill adults, 22\u003c\/p\u003e \u003cp\u003eCardiogenic shock, 23\u003c\/p\u003e \u003cp\u003eAnaphylactic shock, 24\u003c\/p\u003e \u003cp\u003eHypovolemic shock, 24\u003c\/p\u003e \u003cp\u003eSepsis syndromes, 26\u003c\/p\u003e \u003cp\u003eSIRS, sepsis, and septic shock, 26\u003c\/p\u003e \u003cp\u003eMonitoring and treatment priorities in sepsis syndromes, 28\u003c\/p\u003e \u003cp\u003eSepsis diagnosis, 28\u003c\/p\u003e \u003cp\u003eBody temperature, 29\u003c\/p\u003e \u003cp\u003eCultures, 29\u003c\/p\u003e \u003cp\u003eIntravascular catheters, 29\u003c\/p\u003e \u003cp\u003eOther infectious complications in critically ill adults, 29\u003c\/p\u003e \u003cp\u003ePulmonary infections, 29\u003c\/p\u003e \u003cp\u003eUrinary tract infections, 30\u003c\/p\u003e \u003cp\u003eMonitoring during transport, 30\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Monitoring for respiratory dysfunction, 35\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlexander P. Johnson and Jennifer Abraham\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAcid-base disturbances \u0026amp; anion gap, 35\u003c\/p\u003e \u003cp\u003eMetabolic acidosis, 35\u003c\/p\u003e \u003cp\u003eMetabolic alkalosis, 37\u003c\/p\u003e \u003cp\u003eRespiratory acidosis, 37\u003c\/p\u003e \u003cp\u003eRespiratory alkalosis, 38\u003c\/p\u003e \u003cp\u003eMixed acid–base disorders, 38\u003c\/p\u003e \u003cp\u003eOxygenation, 38\u003c\/p\u003e \u003cp\u003eEstimation of the PaO2, 38\u003c\/p\u003e \u003cp\u003eA–a Gradient, 39\u003c\/p\u003e \u003cp\u003ePaO2\/FiO2 (P\/F) ratio, 39\u003c\/p\u003e \u003cp\u003eAcute respiratory failure, 40\u003c\/p\u003e \u003cp\u003eCapnography, 40\u003c\/p\u003e \u003cp\u003eMonitoring ventilation with PetCO2, 40\u003c\/p\u003e \u003cp\u003eMonitoring blood flow, 41\u003c\/p\u003e \u003cp\u003eModes of mechanical ventilation, 41\u003c\/p\u003e \u003cp\u003eContinuous positive airway pressure (CPAP) with pressure support, 41\u003c\/p\u003e \u003cp\u003eSynchronized intermittent mandatory ventilation (SIMV), 42\u003c\/p\u003e \u003cp\u003eAssist\/control ventilation (AC), 42\u003c\/p\u003e \u003cp\u003ePressure control ventilation, 42\u003c\/p\u003e \u003cp\u003eAirway pressure release ventilation (APRV), 42\u003c\/p\u003e \u003cp\u003ePressure-regulated volume control (PRVC), 42\u003c\/p\u003e \u003cp\u003eInverse ratio ventilation, 43\u003c\/p\u003e \u003cp\u003eOscillatory ventilation, 43\u003c\/p\u003e \u003cp\u003eOverview of protective lung ventilation in ARDS, 43\u003c\/p\u003e \u003cp\u003eARDSNet protocol goals, 43\u003c\/p\u003e \u003cp\u003eMonitoring for complications during mechanical ventilation, 43\u003c\/p\u003e \u003cp\u003eHigh peak airway pressures on mechanical ventilation, 43\u003c\/p\u003e \u003cp\u003eResponse to bagging—monitoring and treatment, 44\u003c\/p\u003e \u003cp\u003eAuto-PEEP effect, 44\u003c\/p\u003e \u003cp\u003eWeaning from mechanical ventilation, 44\u003c\/p\u003e \u003cp\u003ePostextubation stridor: monitoring and treatment, 46\u003c\/p\u003e \u003cp\u003eNoninvasive positive pressure ventilation, 47\u003c\/p\u003e \u003cp\u003eTension pneumothorax, 47\u003c\/p\u003e \u003cp\u003eEmergent treatment—needle thoracostomy, 47\u003c\/p\u003e \u003cp\u003eChest radiograph interpretation, 48\u003c\/p\u003e \u003cp\u003eSleep-disordered breathing in the critical care unit, 48\u003c\/p\u003e \u003cp\u003eObstructive sleep apnea, 50\u003c\/p\u003e \u003cp\u003eCentral sleep apnea, 50\u003c\/p\u003e \u003cp\u003eObesity hypoventilation syndrome, 51\u003c\/p\u003e \u003cp\u003eCPAP and BiPAP therapy, 51\u003c\/p\u003e \u003cp\u003eApproach to cardiogenic dyspnea in acute heart failure, 52\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Electrocardiographic monitoring for cardiovascular dysfunction, 57\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCatherine Winkler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 57\u003c\/p\u003e \u003cp\u003eGoals of monitoring, 58\u003c\/p\u003e \u003cp\u003ePost cardiopulmonary resuscitation, 59\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 60\u003c\/p\u003e \u003cp\u003eAcute coronary syndromes, 60\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 62\u003c\/p\u003e \u003cp\u003eCardiac arrhythmias, 64\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 65\u003c\/p\u003e \u003cp\u003eAcute heart failure, 67\u003c\/p\u003e \u003cp\u003eElectrolyte abnormalities, 67\u003c\/p\u003e \u003cp\u003eMonitoring elements, 68\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 68\u003c\/p\u003e \u003cp\u003eCritical illnesses, 68\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 68\u003c\/p\u003e \u003cp\u003eDrug overdose, 69\u003c\/p\u003e \u003cp\u003eEvidenced-based guidelines, 69\u003c\/p\u003e \u003cp\u003eUnnecessary arrhythmia monitoring and underutilization of ischemia and QT-interval monitoring, 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Hemodynamic monitoring in critical care, 73\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKathy J. Booker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eHemodynamic monitoring overview, 73\u003c\/p\u003e \u003cp\u003eHemodynamic monitoring systems, 75\u003c\/p\u003e \u003cp\u003ePulmonary artery catheter monitoring, 75\u003c\/p\u003e \u003cp\u003eCentral venous pressure monitoring and management, 76\u003c\/p\u003e \u003cp\u003eCentral venous pressure trending limitations, 77\u003c\/p\u003e \u003cp\u003eArterial line monitoring and management, 78\u003c\/p\u003e \u003cp\u003eHemodynamic monitoring guidelines and outcomes, 78\u003c\/p\u003e \u003cp\u003eFunctional indicators of hemodynamic monitoring, 79\u003c\/p\u003e \u003cp\u003ePerioperative optimization, 79\u003c\/p\u003e \u003cp\u003eTransesophageal monitoring, 79\u003c\/p\u003e \u003cp\u003eVolume responsiveness, 80\u003c\/p\u003e \u003cp\u003ePulse contour analysis, 81\u003c\/p\u003e \u003cp\u003eFloTrac\/Vigileo®, 82\u003c\/p\u003e \u003cp\u003eTranspulmonary dilution techniques, 82\u003c\/p\u003e \u003cp\u003ePassive leg raising, 83\u003c\/p\u003e \u003cp\u003eSVV protocols for management, 84\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Monitoring for neurologic dysfunction, 87\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJanice L. Hinkle and Carey Heck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePhysiological guidelines, 87\u003c\/p\u003e \u003cp\u003eIncreased intracranial pressure, 87\u003c\/p\u003e \u003cp\u003eDecreased cerebral blood flow, 88\u003c\/p\u003e \u003cp\u003eCerebral response to increased intracranial pressure, 88\u003c\/p\u003e \u003cp\u003eRapid assessment of neurologic dysfunction in intensive care unit patients, 89\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 90\u003c\/p\u003e \u003cp\u003eIntracranial pressure monitoring, 93\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 93\u003c\/p\u003e \u003cp\u003eMeasuring brain temperature, 94\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 95\u003c\/p\u003e \u003cp\u003eBrain tissue O2 monitoring, 95\u003c\/p\u003e \u003cp\u003eMonitoring elements, 95\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 95\u003c\/p\u003e \u003cp\u003eMicrodialysis, 95\u003c\/p\u003e \u003cp\u003eMonitoring elements, 95\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 95\u003c\/p\u003e \u003cp\u003eElectrophysiological monitoring, 96\u003c\/p\u003e \u003cp\u003eMonitoring elements, 96\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 96\u003c\/p\u003e \u003cp\u003eThe BiSpectral index monitoring, 96\u003c\/p\u003e \u003cp\u003eMonitoring elements, 96\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 96\u003c\/p\u003e \u003cp\u003eTranscranial Doppler ultrasonograpy, 97\u003c\/p\u003e \u003cp\u003eMonitoring elements, 97\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 97\u003c\/p\u003e \u003cp\u003eShunts, 98\u003c\/p\u003e \u003cp\u003eMonitoring elements, 98\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 98\u003c\/p\u003e \u003cp\u003eNeuromuscular transmission, 98\u003c\/p\u003e \u003cp\u003eMonitoring elements, 98\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 98\u003c\/p\u003e \u003cp\u003eManagement of cervical stabilization devices, 98\u003c\/p\u003e \u003cp\u003eMonitoring elements, 98\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 99\u003c\/p\u003e \u003cp\u003eInduced coma and sedation protocols, 100\u003c\/p\u003e \u003cp\u003eMonitoring elements, 100\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 100\u003c\/p\u003e \u003cp\u003eResearch-based neurologic protocols, 100\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Monitoring for renal dysfunction, 104\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDawn Cooper\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAcute kidney injury, 104\u003c\/p\u003e \u003cp\u003ePhysiological guidelines, 105\u003c\/p\u003e \u003cp\u003ePrerenal injury, 105\u003c\/p\u003e \u003cp\u003eIntrarenal injury, 106\u003c\/p\u003e \u003cp\u003eAcute tubular necrosis, 107\u003c\/p\u003e \u003cp\u003eAcute intersitial nephritis, 107\u003c\/p\u003e \u003cp\u003ePost renal injury, 108\u003c\/p\u003e \u003cp\u003eMonitoring elements, 108\u003c\/p\u003e \u003cp\u003eHistory and physical assessment, 108\u003c\/p\u003e \u003cp\u003eLaboratory analysis and data trending, 109\u003c\/p\u003e \u003cp\u003eDiagnostic imaging, 111\u003c\/p\u003e \u003cp\u003eRenal biopsy, 111\u003c\/p\u003e \u003cp\u003eEvidenced-based treatment guidelines, 112\u003c\/p\u003e \u003cp\u003ePrevention, 112\u003c\/p\u003e \u003cp\u003eHemodynamic monitoring, 112\u003c\/p\u003e \u003cp\u003eVolume expansion, 112\u003c\/p\u003e \u003cp\u003eManagement of electrolyte and acid–base imbalance, 112\u003c\/p\u003e \u003cp\u003ePharmacologic interventions, 113\u003c\/p\u003e \u003cp\u003ePrevention of radiocontrast nephropathy, 114\u003c\/p\u003e \u003cp\u003eNutrition, 114\u003c\/p\u003e \u003cp\u003eRenal replacement therapy, 114\u003c\/p\u003e \u003cp\u003eIntermittant hemodialysis, 114\u003c\/p\u003e \u003cp\u003eContinuous renal replacement therapies, 114\u003c\/p\u003e \u003cp\u003ePeritoneal dialysis, 115\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Monitoring for blood glucose dysfunction in the intensive care unit, 119\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLaura Kierol Andrews\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDiabetes management in the ICU, 119\u003c\/p\u003e \u003cp\u003eEffects of hyperglycemia, 119\u003c\/p\u003e \u003cp\u003eHyperglycemia management recommendations, 120\u003c\/p\u003e \u003cp\u003eGlucose monitoring, 120\u003c\/p\u003e \u003cp\u003eCarbohydrate administration, 120\u003c\/p\u003e \u003cp\u003eInsulin therapy, 121\u003c\/p\u003e \u003cp\u003eHypoglycemia management, 121\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Monitoring for hepatic and GI dysfunction, 126\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEleanor R. Fitzpatrick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 126\u003c\/p\u003e \u003cp\u003eGastrointestinal dysfunction, 126\u003c\/p\u003e \u003cp\u003eGastrointestinal bleeding, 128\u003c\/p\u003e \u003cp\u003eMonitoring elements: nasogastric decompression, 128\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 129\u003c\/p\u003e \u003cp\u003eGastric pH, 129\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 130\u003c\/p\u003e \u003cp\u003eMonitoring elements: laboratory tests for GI bleeding, 130\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 130\u003c\/p\u003e \u003cp\u003eEndoscopic procedures, 130\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 131\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines for stress ulcers, 132\u003c\/p\u003e \u003cp\u003eMonitoring elements: gastric tonometry and capnometry, 133\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 134\u003c\/p\u003e \u003cp\u003eRadiographic diagnostics, 134\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 135\u003c\/p\u003e \u003cp\u003eUltrasonography, 135\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 135\u003c\/p\u003e \u003cp\u003eIntraabdominal pressure management, 135\u003c\/p\u003e \u003cp\u003eIntraabdominal pressure measurement, 136\u003c\/p\u003e \u003cp\u003eTreatment of abdominal compartment syndrome, 137\u003c\/p\u003e \u003cp\u003eDiagnostics for liver function, 137\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 138\u003c\/p\u003e \u003cp\u003eLiver support devices, 138\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 139\u003c\/p\u003e \u003cp\u003eBalloon tamponade therapy, 139\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 140\u003c\/p\u003e \u003cp\u003eICP monitoring in acute liver failure, 140\u003c\/p\u003e \u003cp\u003eEvidenced-based treatment guidelines, 140\u003c\/p\u003e \u003cp\u003eAscites management, 141\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines: paracentesis, 141\u003c\/p\u003e \u003cp\u003eNutritional assessment and treatment, 142\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 142\u003c\/p\u003e \u003cp\u003eCritical monitoring in acute pancreatitis, 142\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines for acute pancreatitis, 143\u003c\/p\u003e \u003cp\u003eMonitoring elements: pancreatitis, 143\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines for acute pancreatitis, 143\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Traumatic injuries: special considerations, 146\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCatherine Bond and Mary Beth Voights\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePrimary, secondary, and tertiary surveys, 146\u003c\/p\u003e \u003cp\u003eFluid resuscitation, 151\u003c\/p\u003e \u003cp\u003eFluid choice, 151\u003c\/p\u003e \u003cp\u003eEnd points of resuscitation, 152\u003c\/p\u003e \u003cp\u003eIntracompartmental monitoring, 152\u003c\/p\u003e \u003cp\u003eComplications, 153\u003c\/p\u003e \u003cp\u003eThromboembolic events, 153\u003c\/p\u003e \u003cp\u003eAnticoagulation, 154\u003c\/p\u003e \u003cp\u003ePain management, 154\u003c\/p\u003e \u003cp\u003eEarly mobilization, 154\u003c\/p\u003e \u003cp\u003eThoracic injury management, 154\u003c\/p\u003e \u003cp\u003eAbdominal trauma, 155\u003c\/p\u003e \u003cp\u003eAbdominal compartment syndrome, 158\u003c\/p\u003e \u003cp\u003eMusculoskeletal injuries and management, 159\u003c\/p\u003e \u003cp\u003eOngoing hemorrhage, 160\u003c\/p\u003e \u003cp\u003ePelvic fractures, 161\u003c\/p\u003e \u003cp\u003eCrush syndrome management, 161\u003c\/p\u003e \u003cp\u003ePain management in orthopedic injury, 162\u003c\/p\u003e \u003cp\u003eBurns, 162\u003c\/p\u003e \u003cp\u003eBurn classification, 162\u003c\/p\u003e \u003cp\u003eFluid management in burn therapy, 164\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Oncologic emergencies in critical care, 167\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLisa M. Barbarotta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEvolution of oncology critical management, 167\u003c\/p\u003e \u003cp\u003eSepsis in the immunocompromised host, 167\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 167\u003c\/p\u003e \u003cp\u003eAssessment and monitoring in neutropenic patients, 168\u003c\/p\u003e \u003cp\u003eNeutropenia management, 168\u003c\/p\u003e \u003cp\u003eEvidence-based guidelines, 169\u003c\/p\u003e \u003cp\u003eResearch, 171\u003c\/p\u003e \u003cp\u003eStem cell transplant, 171\u003c\/p\u003e \u003cp\u003eInfection, 172\u003c\/p\u003e \u003cp\u003eGraft-versus-host disease, 172\u003c\/p\u003e \u003cp\u003eHepatic veno-occlusive disease, 173\u003c\/p\u003e \u003cp\u003ePulmonary complications, 174\u003c\/p\u003e \u003cp\u003eHematologic complications, 175\u003c\/p\u003e \u003cp\u003eHemorrhagic complications, 175\u003c\/p\u003e \u003cp\u003eThrombocytopenia, 175\u003c\/p\u003e \u003cp\u003eManagement, 176\u003c\/p\u003e \u003cp\u003eThrombotic microangiopathy, 177\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 177\u003c\/p\u003e \u003cp\u003eManagement, 179\u003c\/p\u003e \u003cp\u003eHyperviscosity syndromes, 179\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 179\u003c\/p\u003e \u003cp\u003eManagement, 180\u003c\/p\u003e \u003cp\u003eHyperleukocytosis and leukostasis, 180\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 180\u003c\/p\u003e \u003cp\u003eManagement, 181\u003c\/p\u003e \u003cp\u003eTumor lysis syndrome, 181\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 181\u003c\/p\u003e \u003cp\u003eTreatment, 183\u003c\/p\u003e \u003cp\u003eManagement of electrolyte imbalances, 184\u003c\/p\u003e \u003cp\u003eHyperkalemia, 184\u003c\/p\u003e \u003cp\u003eHyperphosphatemia with secondary hypocalcemia, 184\u003c\/p\u003e \u003cp\u003eHyperuricemia, 185\u003c\/p\u003e \u003cp\u003eAcute kidney injury, 186\u003c\/p\u003e \u003cp\u003eEvidence-based treatment guidelines, 186\u003c\/p\u003e \u003cp\u003eStructural emergencies, 186\u003c\/p\u003e \u003cp\u003eCardiac tamponade, 187\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 187\u003c\/p\u003e \u003cp\u003eManagement, 189\u003c\/p\u003e \u003cp\u003eMalignant airway obstruction, 189\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 189\u003c\/p\u003e \u003cp\u003eManagement, 190\u003c\/p\u003e \u003cp\u003eCarotid blowout syndrome, 192\u003c\/p\u003e \u003cp\u003ePhysiologic guidelines, 192\u003c\/p\u003e \u003cp\u003eManagement, 194\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 End-of-life concerns, 201\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKathy J. Booker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 201\u003c\/p\u003e \u003cp\u003eAssessment and communication issues, 201\u003c\/p\u003e \u003cp\u003eFamily presence, 202\u003c\/p\u003e \u003cp\u003eAdvanced directives, 202\u003c\/p\u003e \u003cp\u003eSurrogate decision making, 202\u003c\/p\u003e \u003cp\u003eDelivering bad news, 204\u003c\/p\u003e \u003cp\u003ePalliative care in the ICU, 204\u003c\/p\u003e \u003cp\u003eSymptom management, 206\u003c\/p\u003e \u003cp\u003eBrain death, 206\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Monitoring for overdoses, 210\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLinda M. Dalessio\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 210\u003c\/p\u003e \u003cp\u003eGeneral management of drug overdoses, 210\u003c\/p\u003e \u003cp\u003eDrug screening, 210\u003c\/p\u003e \u003cp\u003eNew and emerging therapies, 211\u003c\/p\u003e \u003cp\u003eIndexing of drug and toxins seen in overdoses, 212\u003c\/p\u003e \u003cp\u003eAcetaminophen, 213\u003c\/p\u003e \u003cp\u003eDrug overview, 213\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 213\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 213\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents, 213\u003c\/p\u003e \u003cp\u003eSalicylates and nonsteroidal anti-inflammatory drugs, 214\u003c\/p\u003e \u003cp\u003eDrug overview, 214\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 214\u003c\/p\u003e \u003cp\u003eMonitoring, 214\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatment, 215\u003c\/p\u003e \u003cp\u003eMethemoglobin, 215\u003c\/p\u003e \u003cp\u003eDrug overview, 215\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 215\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 216\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatment, 216\u003c\/p\u003e \u003cp\u003eIron, 217\u003c\/p\u003e \u003cp\u003eDrug overview, 217\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 217\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 217\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatment, 217\u003c\/p\u003e \u003cp\u003eDrugs of abuse, 218\u003c\/p\u003e \u003cp\u003eOverview, 218\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 218\u003c\/p\u003e \u003cp\u003eDiagnostic testing, 218\u003c\/p\u003e \u003cp\u003eBenzodiazepines, 218\u003c\/p\u003e \u003cp\u003eDrug overview, 218\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 218\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 219\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 219\u003c\/p\u003e \u003cp\u003eOpiods, 219\u003c\/p\u003e \u003cp\u003eDrug overview, 219\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 219\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 220\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatment, 220\u003c\/p\u003e \u003cp\u003eCocaine, 220\u003c\/p\u003e \u003cp\u003eDrug overview, 221\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 221\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 221\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatment, 222\u003c\/p\u003e \u003cp\u003eAmphetamines, 222\u003c\/p\u003e \u003cp\u003eDrug overview, 222\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 222\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 222\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 223\u003c\/p\u003e \u003cp\u003ePhencyclidine, 223\u003c\/p\u003e \u003cp\u003eDrug overview, 223\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 223\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 223\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 223\u003c\/p\u003e \u003cp\u003eBarbituates, 224\u003c\/p\u003e \u003cp\u003eDrug overview, 224\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 224\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 224\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 224\u003c\/p\u003e \u003cp\u003eHallucinogens, 224\u003c\/p\u003e \u003cp\u003eDrug overview, 224\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 225\u003c\/p\u003e \u003cp\u003eMonitoring and treatment, 225\u003c\/p\u003e \u003cp\u003eClub drugs\/date rape drugs, 225\u003c\/p\u003e \u003cp\u003eDrug overview, 225\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 225\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 226\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 226\u003c\/p\u003e \u003cp\u003eKetamine, 226\u003c\/p\u003e \u003cp\u003eDrug overview, 226\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 226\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 227\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 227\u003c\/p\u003e \u003cp\u003eFake marijuana, 227\u003c\/p\u003e \u003cp\u003eDrug overview, 227\u003c\/p\u003e \u003cp\u003eSymptoms, 227\u003c\/p\u003e \u003cp\u003eDiagnostic testing, 227\u003c\/p\u003e \u003cp\u003eAntidote, 228\u003c\/p\u003e \u003cp\u003eDextromethorphan, 228\u003c\/p\u003e \u003cp\u003eDrug overview, 228\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 228\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 228\u003c\/p\u003e \u003cp\u003eAntidotes, 229\u003c\/p\u003e \u003cp\u003eBath salts, 229\u003c\/p\u003e \u003cp\u003eDrug overview, 229\u003c\/p\u003e \u003cp\u003eSymptoms of overdose\/use, 229\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 229\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 229\u003c\/p\u003e \u003cp\u003eSkeletal muscle relaxants, 230\u003c\/p\u003e \u003cp\u003eDrug overview, 230\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 230\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 230\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 231\u003c\/p\u003e \u003cp\u003ePsychiatric drugs, 231\u003c\/p\u003e \u003cp\u003eDrug overview, 231\u003c\/p\u003e \u003cp\u003eSelective serotonin reuptake inhibitors, 231\u003c\/p\u003e \u003cp\u003eDrug overview, 231\u003c\/p\u003e \u003cp\u003eSymptoms, 231\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 234\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 234\u003c\/p\u003e \u003cp\u003eMonoamine oxidase inhibitors, 234\u003c\/p\u003e \u003cp\u003eDrug overview, 234\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 235\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 235\u003c\/p\u003e \u003cp\u003eAntidotes, 235\u003c\/p\u003e \u003cp\u003eLithium, 236\u003c\/p\u003e \u003cp\u003eDrug overview, 236\u003c\/p\u003e \u003cp\u003eSymptom of overdose, 236\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 236\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 236\u003c\/p\u003e \u003cp\u003eNeuroleptics, 237\u003c\/p\u003e \u003cp\u003eDrug overview, 237\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 237\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 237\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 237\u003c\/p\u003e \u003cp\u003eTricyclic antidepressants, 238\u003c\/p\u003e \u003cp\u003eDrug overview, 238\u003c\/p\u003e \u003cp\u003eSymptoms of overdose, 238\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 238\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 238\u003c\/p\u003e \u003cp\u003eCarbon monoxide, 239\u003c\/p\u003e \u003cp\u003eDrug overview, 239\u003c\/p\u003e \u003cp\u003ePharmacology, 239\u003c\/p\u003e \u003cp\u003eSymptoms, 239\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 239\u003c\/p\u003e \u003cp\u003eAntidotes\/binding agents\/treatments, 240\u003c\/p\u003e \u003cp\u003eHydrocarbons and toxic inhalants, 240\u003c\/p\u003e \u003cp\u003eDrug overview, 240\u003c\/p\u003e \u003cp\u003ePharmacology, 240\u003c\/p\u003e \u003cp\u003eDiagnostic testing and monitoring, 241\u003c\/p\u003e \u003cp\u003eSigns and symptoms, 241\u003c\/p\u003e \u003cp\u003eAntidotes\/treatment, 241\u003c\/p\u003e \u003cp\u003eCardiac medications, 241\u003c\/p\u003e \u003cp\u003eDrug overview, 241\u003c\/p\u003e \u003cp\u003eAntiarrhythmic agents, 246\u003c\/p\u003e \u003cp\u003eToxic alcohols, 248\u003c\/p\u003e \u003cp\u003eDrug overview, 248\u003c\/p\u003e \u003cp\u003eAnticholinergics\/Cholinergics\/Antihistamines (ACA), 251\u003c\/p\u003e \u003cp\u003eDrug overview, 251\u003c\/p\u003e \u003cp\u003eACA symptoms of overdose, 252\u003c\/p\u003e \u003cp\u003eACA diagnostic testing and monitoring, 252\u003c\/p\u003e \u003cp\u003eACA antidotes\/binding agents\/treatment, 252\u003c\/p\u003e \u003cp\u003eAnticonvulsants, 252\u003c\/p\u003e \u003cp\u003eDrug overview, 252\u003c\/p\u003e \u003cp\u003eAnticonvulsants symptoms of overdose, 253\u003c\/p\u003e \u003cp\u003eAnticonvulsants diagnostic testing and monitoring, 253\u003c\/p\u003e \u003cp\u003eAnticonvulsants antidotes\/binding agents, 253\u003c\/p\u003e \u003cp\u003eCommon toxidromes and treatments for poisoning conditions, 253\u003c\/p\u003e \u003cp\u003eAnticholinergic toxidrome, 255\u003c\/p\u003e \u003cp\u003eBenzodiazepine toxidrome, 255\u003c\/p\u003e \u003cp\u003eCholinergic toxidrome, 256\u003c\/p\u003e \u003cp\u003eOpioid toxidrome, 256\u003c\/p\u003e \u003cp\u003eSympathomimetic toxidromes, 256\u003c\/p\u003e \u003cp\u003eRhabdomyolysis syndromes, 257\u003c\/p\u003e \u003cp\u003eTreatment of hyperkalemia, 257\u003c\/p\u003e \u003cp\u003ePackidrome, 257\u003c\/p\u003e \u003cp\u003eAlcohol withdrawal syndrome, 258\u003c\/p\u003e \u003cp\u003eAnion and non-anion gap acidosis and osmolar anion gap, 258\u003c\/p\u003e \u003cp\u003eNon-anion gap acidosis, 259\u003c\/p\u003e \u003cp\u003eOsmolar gap, 259\u003c\/p\u003e \u003cp\u003eOsmolarity corrected for elevated ETOH level, 259\u003c\/p\u003e \u003cp\u003eIndex, 264\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49525397979479,"sku":"9780470958568","price":52.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470958568.jpg?v=1731860360","url":"https:\/\/bookcurl.com\/products\/critical-care-nursing-9780470958568","provider":"Book Curl","version":"1.0","type":"link"}